The Effects of Hormone Therapy and Alen- dronate on Bone Mineral Densities and Bone Metabolism of Postmenopausal Osteopenia.
- Author:
Ji Young JANG
1
;
Jeong Mi PARK
;
Jong Soon CHOI
;
Myoung Sook NOH
;
Eun Hee KONG
;
Wan Kyu EO
;
Heung Yeol KIM
Author Information
1. Department of Family Medicine, Kosin University College of Medicine, Busan, Korea.
- Publication Type:Clinical Trial ; Original Article ; Randomized Controlled Trial
- Keywords:
estrogen;
alendronate;
BMD;
osteopenia
- MeSH:
Alendronate;
Alkaline Phosphatase;
Bone Density*;
Bone Diseases, Metabolic*;
Busan;
Estrogens;
Female;
Femur Neck;
Humans;
Metabolism*;
Osteocalcin;
Osteoporosis;
Prospective Studies;
Spine
- From:Journal of the Korean Academy of Family Medicine
2006;27(2):113-119
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: There have been bone mass studies for the treatment of osteoporosis, nonetheless, little attention has been paid to the management of osteopenia. This study was to evaluate the effects of estrogen, alendronate and their combination on bone mineral density and bone metabolism in the postmenopausal women with osteopenia. METHODS: A total of 150 healthy regional patients with osteopenia from Busan were enrolled in prospective randomized clinical trial and randomly assigned to receive conjugated equine estrogen (group I), alendronate (group II), or combination of the two (group III). Assessments included BMD of L2-4 spines and femur neck by DEXA and markers of bone turnover including serum osteocalcin, total alkaline phosphatase and urine deoxydyridinoline (Dpd). BMD and markers of bone turnover were re-evaluated at 6 and 12 months after the treatment. RESULTS: BMD of the lumbar spines increased significantly at 12 months after treatment in the three groups (P<0.05). BMD of the femur neck increased at 12 months after treatment in the three groups, but significantly in group III (P<0.05). Serum osteocalcin decreased at 12 months after treatment in the three groups, but only significantly in group III. Urine Dpd decreased at 12 months after treatment in three groups, but significantly in group, II and III (P<0.05). Serum total alkaline phosphatase decreased at 12 months after treatment in only group III (P<0.05). There was more favorable benefit for group III in BMD of the lumbar spines and serum osteocalcin and urine Dpd at 12 months after treatment compared to group, II and III (P<0.05). CONCLUSION: These results indicated a favorable benefit of conjugated equine estrogen, alendronate, or combination of the two in BMD and important markers of bone turnover. The combined treatment with conjugated equine estrogen and alendronate was more effective in postmenopausal women with osteopenia. Long-term studies are required to confirm these results.
